Role of activation-induced cytidine deaminase in the progression of follicular lymphoma

Cancer Science

Volumn 103, Issue 3, 2012, Pages 415-421

  Shikata, Hisaharu ^a   Yakushijin, Yoshihiro ^a   Matsushita, Natsuki ^b   Sakai, Akira ^c   Sugita, Atsuro ^a   Nakamura, Naoya ^d   Yamanouchi, Jun ^a   Azuma, Taichi ^a   Hato, Takaaki ^a   Yasukawa, Masaki ^a  

^a EHIME UNIVERSITY HOSPITAL   (Japan)

^b EHIME UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; AICDA (ACTIVATION INDUCED CYTIDINE DEAMINASE); AICDA (ACTIVATION-INDUCED CYTIDINE DEAMINASE); CYTIDINE DEAMINASE; MYC PROTEIN; MYC PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; G1 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ONCOGENE C MYC; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; DISEASE COURSE; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; CELL PROLIFERATION; CYTIDINE DEAMINASE; DISEASE PROGRESSION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84859709743     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02186.x     Document Type: Article

References (38)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-95.
2. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 75-88.
3. Martin A, Bardwell PD, Woo CJ, Fan M, Shulman MJ, Scharff MD. Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas. Nature 2002; 415: 802-6.
4. Smit LA, Bende RJ, Aten J, Guikema JE, Aarts WM, van Noesel CJ. Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinal-center phenotype. Cancer Res 2003; 63: 3894-8.
5. Hardianti MS, Tatsumi E, Syampurnawati M et al. Activation-induced cytidine deaminase expression in follicular lymphoma: association between AID expression and ongoing mutation in FL. Leukemia 2004; 18: 826-31.
6. Rowley JD. Chromosome studies in the non-Hodgkin's lymphomas: the role of the 14;18 translocation. J Clin Oncol 1988; 6: 919-25.
7. McDonnell TJ, Deane N, Platt FM et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88.
8. Dolken G, Illerhaus G, Hirt C, Mertelsmann R. BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol 1996; 14: 1333-44.
9. Yasukawa M, Bando S, Dolken G et al. Low frequency of BCL-2/J(H) translocation in peripheral blood lymphocytes of healthy Japanese individuals. Blood 2001; 98: 486-8.
10. Cullen MH, Lister TA, Brearley RI, Shand WS, Stansfeld AG. Histological transformation of non-Hodgkin's lymphoma: a prospective study. Cancer 1979; 44: 645-51.
11. Bastion Y, Sebban C, Berger F et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997; 15: 1587-94.
12. Montoto S, Davies AJ, Matthews J et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007; 25: 2426-33.
13. Maeshima AM, Omatsu M, Nomoto J et al. Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma: morphological, immunohistochemical, and FISH analyses. Cancer Sci 2008; 99: 1760-8.
14. De Jong D, Voetdijk BM, Beverstock GC, van Ommen GJ, Willemze R, Kluin PM. Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med 1988; 318: 1373-8.
15. Lossos IS, Alizadeh AA, Diehn M et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA 2002; 99: 8886-91.
16. Akasaka T, Lossos IS, Levy R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood 2003; 102: 1443-8.
17. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82: 2289-95.
18. Pinyol M, Cobo F, Bea S et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998; 91: 2977-84.
19. Davies AJ, Rosenwald A, Wright G et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 2007; 136: 286-93.
20. Johnson NA, Savage KJ, Ludkovski O et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114: 2273-9.
21. Tomita N, Tokunaka M, Nakamura N et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 2009; 94: 935-43.
22. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000; 18: 3707-21.
23. Kramer MH, Hermans J, Wijburg E et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152-62.
24. Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009; 23: 777-83.
25. Christie L, Kernohan N, Levison D et al. C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: an adverse prognostic indicator? Leuk Lymphoma 2008; 49: 470-6.
26. Ramiro AR, Jankovic M, Eisenreich T et al. AID is required for c-myc/IgH chromosome translocations in vivo. Cell 2004; 118: 431-38.
27. Revy P, Muto T, Levy Y et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 2000; 102: 565-75.
28. Takizawa M, Tolarova H, Li Z et al. AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. J Exp Med 2008; 205: 1949-57.
29. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
30. Lu R. Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol 2008; 29: 487-92.
31. Wang SA, Wang L, Hochberg EP, Muzikansky A, Harris NL, Hasserjian RP. Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. Am J Surg Pathol 2005; 29: 1490-6.
32. Naresh KN. MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. Haematologica 2007; 92: 267-8.
33. Aukema SM, Siebert R, Schuuring E et al. Double-hit B-cell lymphomas. Blood 2011; 117: 2319-31.
34. Tsai AG, Lu H, Raghavan SC, Muschen M, Hsieh CL, Lieber MR. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell 2008; 135: 1130-42.
35. Dorsett Y, Robbiani DF, Jankovic M, Reina-San-Martin B, Eisenreich TR, Nussenzweig MC. A role for AID in chromosome translocations between c-myc and the IgH variable region. J Exp Med 2007; 204: 2225-32.
36. Chaudhuri J, Tian M, Khuong C, Chua K, Pinaud E, Alt FW. Transcriptiontargeted DNA deamination by the AID antibody diversification enzyme. Nature 2003; 422: 726-30.
37. Zaheen A, Boulianne B, Parsa JY, Ramachandran S, Gommerman JL, Martin A. AID constrains germinal center size by rendering B cells susceptible to apoptosis. Blood 2009; 114: 547-54.
38. Jankovic M, Robbiani DF, Dorsett Y et al. Role of the translocation partner in protection against AID-dependent chromosomal translocations. Proc Natl Acad Sci USA 2010; 107: 187-92.